SPONSORED CONTENT

ACG Acquires Significant Stake in Mumbai-based IQGEN-X

November 03, 2020 23:30 IST
Tennis player James Blake
ACG logo

Mumbai (Maharashtra) [India], Nov 3 (ANI/PRNewswire): ACG, a leading supplier of integrated pharmaceutical manufacturing solutions announced acquisition of a significant stake in Mumbai-based start-up IQGEN-X.

IQGEN-X is a Contract Research Organisation (CRO) delivering niche and complex drug development technologies for the pharmaceutical industry.

The move sees ACG expanding further into the R and D side of drug development and supports a firm group-wide commitment to improving customer experiences throughout the supply and value chains.

The investment by ACG also comes at a critical juncture when the Indian government is at the cusp of announcing a new policy to globally benchmark R and D ecosystem by incentivising innovation and science. The funds so infused by ACG will be utilized for setting up a cGMP facility and also the development and filing of new ANDAs.

"IQGENX's excellent track record in patents and Abbreviated New Drug Application (ANDAs) speaks for itself, and we look forward to benefitting from its niche technology, broad-based expertise and research specialization that has been recognized globally by WHO and the US FDA," said Karan Singh, Managing Director, ACG.

"For ACG, this partnership will immediately help expand our group capabilities, and will accelerate our innovation strategy of bold, disciplined investment and world class execution to drive sustainable long-term growth with drug companies in India and global markets," said Karan Singh.

"We at IQGEN-X are delighted to have ACG as partner whose strong global footprints and excellent operational capabilities, bring great synergy to IQGEN-X's growth strategy. ACG's strategic investment augments our technical expertise, portfolio strategy and corporate vision to create a robust portfolio of limited competition complex products for regulated markets. We believe that this partnership will open several other opportunities which will accelerate growth of both companies," said Dr Mandar M Kodgule, Chairman and CEO, IQGEN-X.

IQGENX was established in October 2016, with a vision of innovative research and technology to produce high quality, affordable, safe, and effective medicines. Its state-of-art R and D facility for niche and complex generic products, expertise in technology transfer, regulatory, IP and compliance, enables it to cater to US, European and other highly regulated markets. Led by healthcare experts and pharmaceutical scientists with over 150 years of combined experience, the company is on the path to grow from a contract research organization (CRO) to a fully integrated pharmaceutical company.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

 

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

ACG Acquires Significant Stake in Mumbai-based IQGEN-X

Mumbai (Maharashtra) [India], Nov 3 (ANI/PRNewswire): ACG, a leading supplier of integrated pharmaceutical manufacturing solutions announced acquisition of a significant stake in Mumbai-based start-up IQGEN-X.

IQGEN-X is a Contract Research Organisation (CRO) delivering niche and complex drug development technologies for the pharmaceutical industry.

The move sees ACG expanding further into the R and D side of drug development and supports a firm group-wide commitment to improving customer experiences throughout the supply and value chains.

The investment by ACG also comes at a critical juncture when the Indian government is at the cusp of announcing a new policy to globally benchmark R and D ecosystem by incentivising innovation and science. The funds so infused by ACG will be utilized for setting up a cGMP facility and also the development and filing of new ANDAs.

"IQGENX's excellent track record in patents and Abbreviated New Drug Application (ANDAs) speaks for itself, and we look forward to benefitting from its niche technology, broad-based expertise and research specialization that has been recognized globally by WHO and the US FDA," said Karan Singh, Managing Director, ACG.

"For ACG, this partnership will immediately help expand our group capabilities, and will accelerate our innovation strategy of bold, disciplined investment and world class execution to drive sustainable long-term growth with drug companies in India and global markets," said Karan Singh.

"We at IQGEN-X are delighted to have ACG as partner whose strong global footprints and excellent operational capabilities, bring great synergy to IQGEN-X's growth strategy. ACG's strategic investment augments our technical expertise, portfolio strategy and corporate vision to create a robust portfolio of limited competition complex products for regulated markets. We believe that this partnership will open several other opportunities which will accelerate growth of both companies," said Dr Mandar M Kodgule, Chairman and CEO, IQGEN-X.

IQGENX was established in October 2016, with a vision of innovative research and technology to produce high quality, affordable, safe, and effective medicines. Its state-of-art R and D facility for niche and complex generic products, expertise in technology transfer, regulatory, IP and compliance, enables it to cater to US, European and other highly regulated markets. Led by healthcare experts and pharmaceutical scientists with over 150 years of combined experience, the company is on the path to grow from a contract research organization (CRO) to a fully integrated pharmaceutical company.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22